Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Millennium reports Velcade sales

Millennium (NASDAQ:MLNM) said that 2007 U.S. sales of Velcade bortezomib rose 20%

Read the full 121 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE